Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW856553 (Losmapimod) Single Dose in Active RA
NCT00256919Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of losmapimod in rheumatoid arthritis (RA) (4 arms), sponsored by GSK. Primary endpoint: C-reactive protein levels. Started Nov 2005; status: completed.
02
Drugs
losmapimod
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00256919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00256919.